Daily U.S. Stock Market News Briefing (November 29, Friday)
Individual Stock News
-
ASML (ASML.O) has received implied permission for clinical trials from the National Medical Products Administration for its Class 1 new drug AZD5462 tablets, which are intended for the treatment of heart failure.
-
The 2024 National Medical Insurance Catalog shows that AstraZeneca (AZN.O) negotiated for the inclusion of the "breast cancer miracle drug" DS8201 injection of trastuzumab deruxtecan in the catalog. Previously, this drug failed to enter the 2023 medical insurance catalog after being listed for formal review in 2023.
-
According to insiders, BlackRock (BLK.N) is close to reaching an agreement to acquire the private credit group HPS Investment Partners, with a final price approaching $12 billion.
-
According to The Information, Amazon (AMZN.O) is developing video artificial intelligence models to hedge its reliance on Anthropic.
-
Sources say that the U.S. Federal Trade Commission (FTC) has launched an antitrust investigation into Microsoft (MSFT.O), covering the company's cloud computing and software licensing business as well as cybersecurity and artificial intelligence products.
-
Vale (VALE.N): The board has approved a dividend of approximately 0.52 Brazilian reais per share.
-
Salesforce (CRM.N) reported on Thursday that online sales during the first half of the U.S. Thanksgiving holiday increased by about 4%, compared to just 2% growth in the same period last year.
-
Miniso (MNSO.N): The company's revenue for the first three quarters reached 12.28 billion yuan, a year-on-year increase of 22.8%.
-
Bilibili (BILI.O) rose 2% in pre-market trading, following news that Taobao's official account is live-streaming sales on Bilibili.
-
The Canadian Competition Bureau has filed a lawsuit against Google (GOOG.O), accusing it of anti-competitive behavior in online advertising in Canada.
-
India has reportedly issued a notice to Volkswagen, stating that it has evaded taxes